Pyoderma gangrenosum: A review and update on new therapies

被引：153
作者：
Miller, Jeremiah [1 ]
Yentzer, Brad A. [1 ]
Clark, Adele [1 ]
Jorizzo, Joseph L. [1 ]
Feldman, Steven R. [1 ,2 ,3 ]
机构：
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Ctr Dermatol Res, Winston Salem, NC 27103 USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Ctr Dermatol Res, Winston Salem, NC 27103 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2010年 / 62卷 / 04期
关键词：
adalimumab; alefacept; clinical trials; efalizumab; etanercept; infliximab; INFLAMMATORY-BOWEL-DISEASE; CROHN-DISEASE; TOPICAL TACROLIMUS; ULCERATIVE-COLITIS; EXTRAINTESTINAL MANIFESTATIONS; SYSTEMIC ABSORPTION; CONTROLLED TRIAL; INFLIXIMAB; ETANERCEPT; ADALIMUMAB;
D O I：
10.1016/j.jaad.2009.05.030
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Pyoderma gangrenosum is a rare and often painful skin disease that can be unpredictable in its response to treatment. There is currently no gold standard of treatment or published algorithm for choice of therapy. The majority of data comes from case studies that lack a standard protocol not only for treatment administration but also for the objective assessment of lesion response to a specific therapy. This review provides an update to the treatment of pyoderma gangrenosum with a particular focus on new systemic therapies. (J Am Acad Dermatol 2010:62:646-54.)
引用
收藏
页码：646 / 654
页数：9
相关论文
共 63 条
  • [1] Treatment of idiopathic pyoderma Gangrenosum with infliximab:: Induction dosing regimen or on-demand therapy?
    Adisen, Esra
    Oztas, Murat
    Guerer, Mehmet Ali
    [J]. DERMATOLOGY, 2008, 216 (02) : 163 - 165
  • [2] Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease
    Batres, LA
    Mamula, P
    Baldassano, RN
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2002, 34 (05) : 558 - 560
  • [3] Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%
    Bellini, V.
    Simonetti, S.
    Lisi, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2008, 22 (01) : 113 - 115
  • [4] A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions
    Bennett, ML
    Jackson, JM
    Jorizzo, JL
    Fleischer, AB
    White, WL
    Callen, JP
    [J]. MEDICINE, 2000, 79 (01) : 37 - 46
  • [5] Bolognia J., 2008, DERMATOLOGY, V1
  • [6] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
    Brooklyn, TN
    Dunnill, MGS
    Shetty, A
    Bowden, JJ
    Williams, JDL
    Griffiths, CEM
    Forbes, A
    Greenwood, R
    Probert, CS
    [J]. GUT, 2006, 55 (04) : 505 - 509
  • [7] Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series
    Charles, Carlos A.
    Leon, Argentina
    Banta, Meggan R.
    Kirsner, Robert S.
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2007, 46 (10) : 1095 - 1099
  • [8] Treatment of pyoderma gangrenosum
    Chow, RKP
    Ho, VC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) : 1047 - 1060
  • [9] Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases
    Cocco, Andrea
    Angelucci, Erika
    Viscido, Angelo
    Caprilli, Renzo
    [J]. INFLAMMATORY BOWEL DISEASES, 2007, 13 (10) : 1317 - 1319
  • [10] Treatment of pyoderma gangrenosum with intravenous immunoglobulin
    Cummins, D. L.
    Anhalt, G. J.
    Monahan, T.
    Meyerle, J. H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (06) : 1235 - 1239
1234567